The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Open accessAbstract
The Microphthalmia-associated transcription factor (MITF) is an important regulator of cell-type specific functions in melanocytic cells. MITF is essential for the survival of pigmented cells, but whereas high levels of MITF drive melanocyte differentiation, lower levels are required to permit proliferation and survival of melanoma cells. MITF is phosphorylated by ERK, and this stimulates its activation, but also targets it for degradation through the ubiquitin-proteosome pathway, coupling MITF degradation to its activation. We have previously shown that because ERK is hyper-activated in melanoma cells in which BRAF is mutated, the MITF protein is constitutively down-regulated. Here we describe another intriguing aspect of MITF regulation by oncogenic BRAF in melanoma cells. We show oncogenic BRAF up-regulates MITF transcription through ERK and the transcription factor BRN2 (N-Oct3). In contrast, we show that in melanocytes this pathway does not exist because BRN2 is not expressed, demonstrating that MITF regulation is a newly acquired function of oncogenic BRAF that is not performed by the wild-type protein. Critically, in melanoma cells MITF is required downstream of oncogenic BRAF because it regulates expression of key cell cycle regulatory proteins such as CDK2 and CDK4. Wild-type BRAF does not regulate this pathway in melanocytes. Thus, we show that oncogenic BRAF exerts exquisite control over MITF on two levels. It downregulates the protein by stimulating its degradation, but then counteracts this by increasing transcription through BRN2. Our data suggest that oncogenic BRAF plays a critical role in regulating MITF expression to ensure that its protein levels are compatible with proliferation and survival of melanoma cells. We propose that its ability to appropriate the regulation of this critical factor explains in part why BRAF is such a potent oncogene in melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“position 600 (V600E) [3].”
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Self-citationGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 5×
“Binding sites previously identified in the MITF promoter are indicated [10].”
BackgroundInfluentialMcGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
Massagué, J., & Gomis, R. R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.033 · Cited by 721
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 630
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness
Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Hoek, K. S., Testori, A., Larue, L., & Goding, C. R. (2006) · Genes & Development · doi:10.1101/gad.406406 · Cited by 608
Wu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Self-citationDu, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression
Carreira, S., Goodall, J., Aksan, I., La Rocca, S. A., Galibert, M.-D., Denat, L., Larue, L., & Goding, C. R. (2005) · Nature · doi:10.1038/nature03269 · Cited by 395
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
V599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
Self-citationMutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
Du, J., Miller, A. J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., & Fisher, D. E. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63657-7 · Cited by 313
Loercher, A. E., Tank, E. M. H., Delston, R. B., & Harbour, J. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410115 · Cited by 266
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 232
Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F., & Hersey, P. (2007) · Modern Pathology · doi:10.1038/modpathol.3800750 · Cited by 202
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196
Self-citationThe Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation
GOODALL, J. C., Wellbrock, C., Dexter, T. J., Roberts, K., Marais, R., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2923-2931.2004 · Cited by 126
Self-citationSalti, G. I., Manougian, T., Farolan, M. J., Shilkaitis, A. L., Majumdar, D., & Gupta, T. K. D. (2000) · PubMed · Cited by 120
Cook, A. L., DONATIEN, P. D., Smith, A. G., Murphy, M., Jones, M. K., Herlyn, M., Bennett, D. C., Leonard, J. H., & Sturm, R. A. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12562.x · Cited by 105
THOMSON, J. A. F., Murphy, K., Baker, E. K., et al. (1995) · PubMed · Cited by 85
(2002) · PubMed · Cited by 79
Cited by
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
“The relationship between BRAF and MITF is poorly understood because oncogenic BRAF and the ERK pathway promote MITF activation but also lead to its degradation (Hemesath et al., 1998; Wu et al., 2000; Wellbrock and Marais, 2005; Wellbrock et al., 2008; Boni et al., 2010).”
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Cancer stem cells versus phenotype‐switching in melanoma
Hoek, K. S., & Goding, C. R. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00757.x · Cited by 506
An integrated approach to uncover drivers of cancer
Akavia, U. D., Litvin, O., Kim, J., Sanchez-Garcia, F., Kotliar, D., Causton, H. C., Pochanard, P., Mozes, E., Garraway, L. A., & Pe'er, D. (2010) · Cell · doi:10.1016/j.cell.2010.11.013 · Cited by 484
Metadata
- Authors
- Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-07-16
- Volume
- 3
- Issue
- 7
- Pages
- e2734
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2035939293
- Cited by
- 278
- References
- 28
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.